RESEARCH TRIANGLE PARK, N.C., Sept. 30 /PRNewswire/ — A global
pharmaceutical company has initiated a prospective trial to
evaluate the impact of insulin guidelines developed by the Indian
National Consensus group in collaboration with Max Neeman, a
leading India-based Contract Research Organization. The goal is to
provide simple management to the Type II Diabetes patient dependent
on insulin. The study will bring out a comparison between the
routine clinical practice and the therapy decided as per the
Insulin guidelines.
This large Phase IV study encompasses the northern, southern,
western and eastern parts of India with over 1,200 sites and aims
to enroll over 25,000 Type II Diabetics. Max Neeman is responsible
for site management of all locations across the country and for
achieving the enrollment target. To date, the team has successfully
enrolled over 12,000 patients in 2 months time and will achieve the
target before the stipulated time.
Max Neeman is experienced in endocrinology/metabolic studies
having been awarded numerous diabetic trials to date with 98%
patient retention rate and target enrollment met by the
deadline.
About Max Neeman International
Max Neeman International is one of the leading CROs in India.
Our specialty is that we offer services for the successful conduct
of Phase I-IV clinical and device trials for small and mid-sized
international and national Pharmaceutical, Biotechnology, Medical
Device and Nutraceutical companies in compliance with ICH GCP
standards. Operational since 2001, Max Neeman is an ISO 9001:2008
certified CRO for Monitoring, Site Management and Data Management
Services. The company is presently active in over 31 cities with 6
regional offices. Contact Donald Swankie, Vice President of
Business Development via email to
donald.swankie@neeman-medical.com or call +1.919.424.3345.
For more information please visit
‘/>”/>
SOURCE